A case report of digestive tract perforation caused by rituximab
Rituximab is a mouse derived immunoglobulin monoclonal antibody against CD20 antigen,which is widely used in the treatment of diffuse large B-cell lymphoma(DLBCL).The main adverse reaction(ADR)is gastrointestinal reaction,but there are few cases of gastrointestinal perforation.At present,most of the literature about this ADR at home and abroad is related to primary gastrointestinal lymphoma.Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin lymphoma(NHL).However,there are few reports about gastrointestinal tract perforation caused by lymphoma outside gastrointestinal tract,but the consequences are more serious.A case of digestive tract perforation in a patient with DLBCL treated with rituximab is reported in this paper,and the clinical manifestations,laboratory examination,imaging features and treatment plan of the patient are reported.Meanwhile,combined with related literature,the mechanism of the drug and the diagnosis and treatment of the disease are discussed,which provides reference for clinical medication safety and reduces the occurrence of ADRs.
RituximabGastrointestinal perforationDiffuse large B-cell lymphomaNon-Hodgkin lymphoma
万方数据
维普
